Robeco Institutional Asset Management B.V. grew its stake in shares of Laboratory Corporation of America Holdings (NYSE:LH) by 13.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,319 shares of the medical research company’s stock after buying an additional 1,880 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Laboratory Corporation of America Holdings were worth $2,464,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Oppenheimer & Co. Inc. grew its stake in shares of Laboratory Corporation of America Holdings by 0.6% in the first quarter. Oppenheimer & Co. Inc. now owns 2,411 shares of the medical research company’s stock worth $346,000 after purchasing an additional 15 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Laboratory Corporation of America Holdings in the first quarter worth about $208,000. Tudor Investment Corp ET AL grew its stake in shares of Laboratory Corporation of America Holdings by 27.8% in the first quarter. Tudor Investment Corp ET AL now owns 2,300 shares of the medical research company’s stock worth $330,000 after purchasing an additional 500 shares during the last quarter. OLD Mutual Customised Solutions Proprietary Ltd. grew its stake in shares of Laboratory Corporation of America Holdings by 13.1% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 4,525 shares of the medical research company’s stock worth $649,000 after purchasing an additional 525 shares during the last quarter. Finally, Colony Group LLC grew its stake in shares of Laboratory Corporation of America Holdings by 46.8% in the first quarter. Colony Group LLC now owns 2,430 shares of the medical research company’s stock worth $349,000 after purchasing an additional 775 shares during the last quarter. 93.39% of the stock is currently owned by hedge funds and other institutional investors.

In other Laboratory Corporation of America Holdings news, insider F Samuel Eberts III sold 31,500 shares of the company’s stock in a transaction dated Friday, August 25th. The shares were sold at an average price of $155.22, for a total value of $4,889,430.00. Following the transaction, the insider now directly owns 31,894 shares in the company, valued at approximately $4,950,586.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David P. King sold 132,713 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $157.06, for a total transaction of $20,843,903.78. The disclosure for this sale can be found here. Insiders sold a total of 212,000 shares of company stock worth $33,229,265 over the last 90 days. Insiders own 0.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Robeco Institutional Asset Management B.V. Buys 1,880 Shares of Laboratory Corporation of America Holdings (LH)” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://theolympiareport.com/2017/11/01/robeco-institutional-asset-management-b-v-buys-1880-shares-of-laboratory-corporation-of-america-holdings-lh.html.

Shares of Laboratory Corporation of America Holdings (LH) opened at 153.71 on Wednesday. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22. The firm has a 50-day moving average of $151.96 and a 200 day moving average of $149.63. The stock has a market capitalization of $15.65 billion, a price-to-earnings ratio of 21.53 and a beta of 0.92.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, topping the Zacks’ consensus estimate of $2.38 by $0.08. The business had revenue of $2.60 billion for the quarter, compared to the consensus estimate of $2.55 billion. Laboratory Corporation of America Holdings had a net margin of 7.40% and a return on equity of 16.75%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.25 EPS. On average, equities research analysts predict that Laboratory Corporation of America Holdings will post $9.52 EPS for the current year.

LH has been the topic of several recent analyst reports. Barclays PLC raised their target price on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Wells Fargo & Company initiated coverage on Laboratory Corporation of America Holdings in a research note on Thursday, October 12th. They issued an “outperform” rating and a $175.00 target price on the stock. Jefferies Group LLC reissued a “hold” rating and issued a $170.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Wednesday, September 13th. Zacks Investment Research raised Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $180.00 target price (up from $175.00) on shares of Laboratory Corporation of America Holdings in a research note on Monday, September 11th. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Laboratory Corporation of America Holdings currently has a consensus rating of “Buy” and a consensus price target of $169.00.

Laboratory Corporation of America Holdings Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.